Jiangxi Fushine Pharmaceutical Performance dei guadagni passati
Il passato criteri di controllo 0/6
Jiangxi Fushine Pharmaceutical's earnings have been declining at an average annual rate of -66.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 2.1% per year.
Informazioni chiave
-66.4%
Tasso di crescita degli utili
-67.5%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore | 10.9% |
Tasso di crescita dei ricavi | 2.1% |
Rendimento del capitale proprio | -8.4% |
Margine netto | -13.9% |
Ultimo aggiornamento sui guadagni | 30 Sep 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Ripartizione dei ricavi e delle spese
Come Jiangxi Fushine Pharmaceutical guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Sep 24 | 1,300 | -181 | 165 | 89 |
30 Jun 24 | 1,436 | -164 | 172 | 93 |
31 Mar 24 | 1,552 | -169 | 184 | 94 |
31 Dec 23 | 1,610 | -201 | 194 | 97 |
30 Sep 23 | 1,701 | -269 | 178 | 85 |
30 Jun 23 | 1,672 | -246 | 180 | 82 |
31 Mar 23 | 1,643 | -200 | 174 | 80 |
01 Jan 23 | 1,647 | -141 | 181 | 77 |
30 Sep 22 | 1,596 | -66 | 198 | 82 |
30 Jun 22 | 1,485 | -58 | 193 | 79 |
31 Mar 22 | 1,437 | 2 | 178 | 76 |
01 Jan 22 | 1,430 | 49 | 167 | 79 |
30 Sep 21 | 1,450 | 187 | 145 | 82 |
30 Jun 21 | 1,452 | 252 | 126 | 80 |
31 Mar 21 | 1,521 | 310 | 130 | 81 |
31 Dec 20 | 1,493 | 319 | 125 | 77 |
30 Sep 20 | 1,496 | 383 | 124 | 64 |
30 Jun 20 | 1,578 | 411 | 126 | 66 |
31 Mar 20 | 1,426 | 336 | 132 | 62 |
31 Dec 19 | 1,354 | 306 | 124 | 59 |
30 Sep 19 | 1,238 | 238 | 118 | 51 |
30 Jun 19 | 1,134 | 177 | 118 | 51 |
31 Mar 19 | 1,154 | 186 | 115 | 54 |
31 Dec 18 | 1,163 | 195 | 114 | 53 |
30 Sep 18 | 1,147 | 211 | 118 | 61 |
30 Jun 18 | 1,106 | 208 | 92 | 69 |
31 Mar 18 | 1,033 | 189 | 94 | 54 |
31 Dec 17 | 958 | 178 | 100 | 44 |
30 Sep 17 | 906 | 182 | 111 | 27 |
30 Jun 17 | 875 | 189 | 146 | 0 |
31 Mar 17 | 834 | 188 | 140 | 0 |
31 Dec 16 | 764 | 174 | 134 | 0 |
30 Sep 16 | 705 | 161 | 120 | 0 |
30 Jun 16 | 667 | 139 | 104 | 0 |
31 Mar 16 | 606 | 111 | 93 | 0 |
31 Dec 15 | 580 | 94 | 84 | 0 |
31 Mar 15 | 530 | 60 | 70 | 0 |
31 Dec 14 | 511 | 53 | 68 | 0 |
31 Dec 13 | 443 | 45 | 55 | 0 |
Guadagni di qualità: 300497 is currently unprofitable.
Margine di profitto in crescita: 300497 is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 300497 is unprofitable, and losses have increased over the past 5 years at a rate of 66.4% per year.
Accelerare la crescita: Unable to compare 300497's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: 300497 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Rendimento del capitale proprio
ROE elevato: 300497 has a negative Return on Equity (-8.36%), as it is currently unprofitable.